demonstrating that, among patients with surgically treated pancreatic cancer, statin users, especially those employing moderate-to-high dosages of simvastatin, had a signifi cantly improved overall survival, also when this was adjusted for multiple confounders. Th is is an interesting fi nding, confi rmed by similar recent results from the SEERMedicare database ( 2 ). Although we agree that the use of statins in patients operated for pancreatic cancer merits further investigation, we think that some additional points might need discussion to help clarifying the authors' fi ndings.
To the Editor: We read the article by Dumortier et al. ( 1 ) with interest. Th is elegant study, in a large number of patients with a long-term follow-up, raises the concern regarding recurrent alcoholic cirrhosis (RAC) aft er liver transplantation (LTx) for end-stage alcoholic liver disease (ALD).
In our single center study, 204 patients were transplanted for ALD between 1994 and 2011, of which 193 patients survived >6 months aft er LTx ( 2 ) . Mean follow-up aft er LTx was 5 years. A total of 27.5% (53/193) of the patients had an alcoholic relapse defi ned as any alcohol use. In support of the fi ndings by Dumortier et al.
( 1 ), 7.5% (4/53) of them developed biopsy proven RAC, despite our signifi cantly shorter follow-up aft er LTx.
However, as briefl y touched by the authors, de novo malignancy and not RAC is the major determinant of mortality in patients transplanted for ALD. In our We interrogated our single-center database of 356 consecutive pancreatic cancer patients to analyze these two issues and found no protective eff ect of the use of either statins, aspirin, metformin, or any of their combination in terms of overall survival. As expected, however, only 17.7% of our patients used statins (5.6% simvastatin). Notably, when considering only 85 resected patients, still no diff erence was found between active users and non-users of statins (hazard ratio (HR) 1.06; 95% confi dence interval (CI) 0.5-2.2) or aspirin (HR 0.9; 95% CI 0.4-1.9), metformin (HR 0.45; 95% CI 0.04-4.2), or statin and aspirin combination (HR 0.54; 95% CI 0.2-1.4).
Finally, as far as the mechanisms by which simvastatin might improve survival, the authors do not cite the possible direct eff ect on the risk of venous thromboembolism. Venous thromboembolism is a rather frequent event in patients with pancreatic cancer, with serious consequences also in terms of survival, and the use of both statins and aspirin seems to reduce this risk in cancer patients ( 4 ) .
